Debamestrocel

DB17934InvestigationalCell transplant therapies

Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis...

Mechanism: Pharmacologically active on BDNF/NT-3 growth factors receptor
Curator reviewed
Also known as: AUTOLOGOUS MESENCHYMAL STROMAL CELLS (MSC) SECRETING NEUROTROPHIC FACTORS (NTF) · AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS · AUTOLOGOUS MSC-NTF

Resolves to

Compound

UNIIGPC34QP6X6

Targets

Q16620NTRK2

What you can answer from here — as of July 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Debamestrocel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account